NovaMedica is in advanced negotiations to secure Russia and CIS rights for a wide range of innovative Products. We are seeking specialty pharmaceutical drugs and devices from various potential US and European partners (including Domain Associates, Inc. portfolio companies) spanning several high-growth therapeutic areas in hospital inpatient, hospital outpatient and specialty care clinical contexts. Products can be both FDA/EMA approved and phase 2B/3 late-stage development. Please check back regularly as we grow our pipeline to serve this exciting market.
Grand finale from a veritable stalwart of neuroscience
09 November 2023
Battle of pharma advocates – in search of the ideal migraine therapy
09 November 2023
31 October 2023
Long COVID study expanded across Europe
30 November 2023
Ethical, Regulatory, and Operational Considerations for Cell and Gene Therapy Research in Children
30 November 2023
Prevention, Treatment for Migraine Rapidly Evolves, Calling for Development of Novel Drugs
29 November 2023
Imaging AI hogs the spotlight at RSNA, with debuts from GE, Siemens, Philips
29 November 2023